Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTT-004
- Development stage
- Preclinical
- Lead developer
- NTT Biopharma
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
NTT-004 is an experimental therapeutic candidate developed by NTT Biopharma, currently in preclinical development. It consists of an antisense oligonucleotide (ASO) encapsulated within mesoporous silica nanoparticles (MSN). This delivery platform is designed to enhance the stability and cellular uptake of the ASO payload. NTT-004 is being investigated for the treatment of solid tumors and wet age-related macular degeneration (Wet-AMD). For the Wet-AMD indication, the drug is being developed as an eyedrop formulation, which aims to provide a non-invasive alternative to the standard-of-care intravitreal injections. The specific molecular target of the antisense oligonucleotide has not been publicly disclosed by the developer.
Beyond the preview
Go deeper on NTT-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTT-004.